In vivo Evaluation of Retinal and Choroidal Structure in a Mouse Model of Long-Lasting Diabetes. Effect of Topical Treatment with Citicoline
DOI:
https://doi.org/10.12974/2309-6136.2015.03.01.1Keywords:
Diabetes, diabetic retinopathy, neuroprotection, citicoline.Abstract
Recent evidences indicate early, diabetes-driven, retinal neurodegeneration as the origin of diabetic retinopathy. To verify the possibility to prevent the disease, we investigated in a mouse model of type 1 diabetes the effect of long-lasting hyperglycemia on retinal and choroidal structures and, in parallel, we tested the effect of topical treatment with the neuroprotective agent citicoline. Forty wild-type C57B6 mice were included in this study. Diabetes was induced by a single intravenous injection of alloxan. Five animals were considered as sham-treated controls, 15 animals as sham-treated diabetic mice, 5 animals as citicoline-treated controls and 15 animals as citicoline-treated diabetic mice. After eight months of diabetes in vivo analysis of the retina was performed using the Spectralis HRA (Heidelberg Retinal Angiography) + OCT. Neuroretinal abnormalities, in particular a significant narrowing of Retinal Nerve Fiber Layer (19.3 ± 2.2 vs 23.3 ± 2.4, ?m ± SD, p=0.01), Ganglion Cells/Inner Plexiform Layer (54.3 ± 5.1 vs 62.6 ± 4.0, p=0.03), Ganglion Cells Complex (73.9 ± 4.8 vs 83.8 ± 3.4, p=0.003) and Retinal thickness (223.8 ± 3.9 vs 236.7 ± 5.8, p=0.0004) were detected in the diabetic mouse that showed also a significant reduction of Choroidal thickness (67.4 ± 3.3 vs 84.7 ± 1.9, p=0.0001). In line with the hypothesis that neuroprotection might help preventing diabetic retinopathy, neuroretinal but not choroidal (choroid lacks a neuronal component) dysfunctions were prevented by citicoline. Altogether these findings demonstrate that diabetes-driven neuroretinal dysfunctions can be monitored in vivo by OCT in the mouse. Retinal neuroprotection as obtained by topical citicoline protects from these abnormalities suggesting this approach as a possible way to prevent diabetic retinopathy.
References
Fong DS, Aiello LP, Ferris FL 3rd and Klein R. Diabetic retinopathy. Diabetes Care 2004; 10: 2540-53. http://dx.doi.org/10.2337/diacare.27.10.2540
Lorenzi M and Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 2001; 44: 791-804. http://dx.doi.org/10.1007/s001250100544
Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG and Sandirasegarane L. Simpson IA; JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006; 55: 2401-11. http://dx.doi.org/10.2337/db05-1635
Barber AJ, Gardner TW and Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci 2011; 52: 1156-63. http://dx.doi.org/10.1167/iovs.10-6293
Lieth E, Gardner TW, Barber AJ and Antonetti DA. Penn State Retina Research Group. Retinal neurodegeneration: early pathology in diabetes. Clin Exp Ophthalmol 2000; 28: 3-8. http://dx.doi.org/10.1046/j.1442-9071.2000.00222.x
Rungger-Brandle E, Dosso AA and Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 2000; 41: 1971-80.
Fletcher EL, Phipps JA and Wilkinson-Berka JL. Dysfunction of retinal neurons and glia during diabetes. Clin Exp Optom 2005; 88: 132-45. http://dx.doi.org/10.1111/j.1444-0938.2005.tb06686.x
Oshitari T, Fujimoto N and Adachi-Usami E. Citicoline has a protective effect on damaged retinal ganglion cells in mouse culture retina. Neuroreport 2002; 13: 2109-11. http://dx.doi.org/10.1097/00001756-200211150-00023
Oshitari T, Yoshida-Hata N and Yamamoto S. Effect of neurotrophic factors on neuronal apoptosis and neurite regeneration in cultured rat retinas exposed to high glucose. Brain Res 2010; 1346: 43-51. http://dx.doi.org/10.1016/j.brainres.2010.05.073
Matteucci A, Varano M, Gaddini L, Mallozzi C, Villa M, Pricci F and Malchiodi-Albedi F. Neuroprotective effects of citicoline in in vitro models of retinal neurodegeneration. Int J Mol Sci 2014; 15: 6286-97. http://dx.doi.org/10.3390/ijms15046286
Ottobelli L, Manni GL, Centofanti M, Iester M, Allevena F and Rossetti L. Citicoline oral solution in glaucoma: is there a role in slowing disease progression? Ophthalmologica 2013; 229: 219-26. http://dx.doi.org/10.1159/000350496
Roberti G, Tanga L, Parisi V, Sampalmieri M, Centofanti M and Manni G. A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy. Indian J Ophthalmol 2014; 62: 549-53. http://dx.doi.org/10.4103/0301-4738.133484
Parisi V, Centofanti M, Ziccardi L, Tanga L, Michelessi M, Roberti G and Manni G. Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2015 May 26. http://dx.doi.org/10.1007/s00417-015-3044-9
Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E and Ulus IH. Peripheral administration of CDP- choline and its cholinergic metabolites increases serum insulin: muscarinic and nicotinic acetylcholine receptors are both involved in their actions. Neurosci Lett 2008; 431: 71-6. http://dx.doi.org/10.1016/j.neulet.2007.11.024
Kern TS, Tang J and Berkowitz BA. Validation of structural and functional lesions of diabetic retinopathy in mice. Mol Vis 2010; 16: 2121-31.
Martin PM, Roon P, Van Ells TK, Ganapathy V and Smith SB. Death of retinal neurons in streptozocin-induced diabetic mice. Invest Ophthalmol Vis Sci 2004; 45: 3330-6. http://dx.doi.org/10.1167/iovs.04-0247
Ferguson LR, Balaiya S, Grover S and Chalam KV. Modified protocol for in vivo imaging of wild-type mouse retina with customized miniature spectral domain optical coherence tomography (SD-OCT) device. Biol Proced Online 2012; 14: 9-11. http://dx.doi.org/10.1186/1480-9222-14-9
Lenzen S. The mechanisms of alloxan- and streptozotocininduced diabetes. Diabetologia 2008; 51: 216- 26. http://dx.doi.org/10.1007/s00125-007-0886-7
Iwase T, Oveson BC, Hashida N, Lima e Silva R, Shen J, Krauss AH, Gale DC, Adamson P and Campochiaro PA. Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit. Invest Ophthalmol Vis Sci 2013; 54: 503-11. http://dx.doi.org/10.1167/iovs.12-10473
Regatieri CV, Branchini L, Carmody J, Fujimoto JG and Duker JS. Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography. Retina 2012; 32: 563-8. http://dx.doi.org/10.1097/IAE.0b013e31822f5678
Xu J, Xu L, Du KF, Shao L, Chen CX, Zhou JQ, Wang YX, You QS, Jonas JB and Wei WB. Subfoveal Choroidal Thickness in Diabetes and Diabetic Retinopathy. Ophthalmology 2013; 20: 2023-8. http://dx.doi.org/10.1016/j.ophtha.2013.03.009
Ozawa Y, Kurihara T, Sasaki M, et al. Neural degeneration in the retina of the streptozotocin- induced type 1 diabetes model. Exp Diabetes Res 2011: 108328. Epub 2011 Nov 17. http://dx.doi.org/10.1155/2011/10832